Kura Oncology (KURA) Operating Leases (2020 - 2026)

Kura Oncology (KURA) has 7 years of Operating Leases data on file, last reported at $13.2 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 68.08% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 68.08% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, up 82.45% from the prior year.
• Operating Leases for Q1 2026 stood at $13.2 million, up from $9.5 million in the prior quarter.
• Over the last five years, Operating Leases for KURA reached as high as $13.2 million in Q1 2026 and fell as low as $1.5 million in Q2 2023.
• Historically, Operating Leases has averaged $5.9 million across 5 years, with a median of $5.8 million in 2024.
• Across the five-year window, Operating Leases slumped 59.61% in 2023 and surged 301.58% in 2024, its largest moves.
• Year by year, Operating Leases stood at $2.5 million in 2022, then surged by 149.69% to $6.4 million in 2023, then retreated by 18.42% to $5.2 million in 2024, then jumped by 82.45% to $9.5 million in 2025, then soared by 39.84% to $13.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $13.2 million in Q1 2026, $9.5 million in Q4 2025, and $8.4 million in Q3 2025.